Skip to content

Protocols of IVF/ICSI in Poor Responders

Minimal Stimulation in a Combined Letrozole Antagonist Protocol Versus Microflare Protocol in Poor Responders Undergoing Invitrofertilization/ Intracytoplasmic Sperm Injection; Randomized Parallel Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04356105
Enrollment
132
Registered
2020-04-22
Start date
2020-06-01
Completion date
2021-10-31
Last updated
2021-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Brief summary

Comparing two ovarian induction protocols in poor responders in IVF/ICSI cycles

Detailed description

The two groups of poor responders are randomized into either; a minimal dose stimulation protocol involving letrozole, recombinant FSH and GnRH antagonist versus a microflare conventional protocol with OCP, GnRH agonist and high dose recombinant FSH, in their IVF/ICSI cycles, primary outcome will be the number of oocytes retrieved.

Interventions

DRUGMinimal stimulation protocol

Letrozole, Recombinant FSH, GnRH antagonist

DRUGMicroflare protocol

OCP, GnRH agonist, Recombinant FSH

PROCEDUREIVF/ICSI cycle

Involving ovum pickup and embryo transfer

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Two groups of poor ovarian responders to be given two different induction protocols at the same time duration of the study

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 43 Years
Healthy volunteers
Yes

Inclusion criteria

1- More than 1 year of infertility 2 - Poor ovarian responder according to the Bologna criteria: 1. Advanced maternal age 2. Previous poor ovarian response 3. Abnormal tests of ovarian reserve (AFC \< 5-7, AMH \<0.5-1.1 ng/ml)

Exclusion criteria

1. Age \> 43 years 2. baseline FSH \>15 mIU/ml 3. Previous ovarian surgery 4. Ovarian endometrioma 5. Uterine anomaly or myoma 6. Any medical disorder 7. Any hormonal disorder eg. hyperprolactinemia 8. BMI \> 30 kg/m2 9. Severe male factor

Design outcomes

Primary

MeasureTime frameDescription
Number of oocytes retrieved10 to 14 daysthe number of oocytes collected from each participants in the two groups on the day of ovum pickup

Secondary

MeasureTime frameDescription
Number of MII oocytes retrieved10 to 14 daysThe mature oocytes colloected on the day of ovum pickup
Number of fertilized oocytes2 daysNumber of oocytes fertilized
Number of embryos transferredDay 3 after ovum pickupNumber of embryos transferred in the induction cycle
Number of embryos cryopreservedDay 3 after ovum pickupAny surplus good quality embryos available for cryopreservation
Chemical pregnancy rate14 days after embryo ransferPositive pregnancy test
Ongoing pregnancy rate12 weekspregnancy beyond 12 weeks
Live birth rate28 to 40 weeksDelivery beyond 28 weeks
Clinical pregnancy rate5 to 7 weeks after embryo transferPositive heart beat
Early miscarriage rate12 weeksloss of pregnancy before 12 weeks

Other

MeasureTime frameDescription
Cancellation rate10 to 14 daysNumber of cycles not reaching ovum pickup
Total dose of recombinant FSH10 to 14 daysThe mean total dose of recombinant FSH used in the cycle of treatment

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026